A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

Vigil on Wednesday said it is ending a Phase 2 study of iluzanebart in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, or ALSP, after the drug showed no ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Sanofi has agreed to acquire US-based Blueprint Medicines for an equity value of $9.1bn to bolster its immunology pipeline ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

French pharmaceutical giant Sanofi is set to acquire U.S.-based Blueprint Medicines Corporation in a deal worth up to $9.5 ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

Global healthcare company Sanofi, headquartered in Paris, France, is announcing another pricey purchase in the U.S.

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.